Abstract:Background: Type-2 diabetes is a chronic progressive metabolic disease resulting in severe vascular complications and mortality risk. Recently, DPP-4 inhibitors are conceived as a favorable class of agents for the treatment of type 2 diabetes due to the minimal side effects. Methods: Sitagliptin is the first medicine approved for DPP-4 inhibitor. Its structure involved three fragments: 2,4,5-triflorophenyl fragment pharmacophore, enantiomerically β-amino carbonyl linker, and tetrahydrotriazolopyridine. Herein, we are drawn to the possibility of substituting tetrahydrotriazolopyridine motif present in Sitagliptin with a series of new fused pyrazolopyrimidine bicyclic fragment to investigate potency and safety. Results: Two series of fused 6-(aminomethyl)pyrazolopyrimidine and 6-(hydroxymethyl)pyrazolopyrimidine derivatives containing β-amino ester or amide as linkers were successfully designed for the new DPP-4 inhibitors. Most fused 6-methylpyrazolopyrimidines were evaluated against DPP-4 inhibition and selectivity capacity. Based on research study, β-amino carbonyl fused 6-(hydroxymethyl)pyrazolopyrimidine possesses the significant DPP-4 inhibition (IC50 ≤ 59.8 nM) and presents similar with Sitagliptin (IC50 = 28 nM). Particularly, they had satisfactory selectivity over DPP-8 and DPP-9, except for QPP. Conclusion: β-Amino esters and amides fused 6-(hydroxymethyl)pyrazolopyrimidine were developed as the new DPP-4 inhibitors. Those compounds with a methyl group or hydrogen in N-1 position and methyl substituted group in C-3 of pyrazolopyrimidine moiety showed better potent DPP-4 inhibition (IC50 = 21.4–59.8 nM). Furthermore, they had satisfactory selectivity over DPP-8 and DPP-9 Finally, the docking results revealed that compound 9n was stabilized at DPP-4 active site and would be a potential lead drug.

Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Synthesis, Biological Assay in Vitro and Molecular Docking Studies of New Imidazopyrazinone Derivatives As Potential Dipeptidyl Peptidase IV Inhibitors.

Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.

Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Synthesis of β-Amino Carbonyl 6-(Aminomethyl)- and 6-(Hydroxymethyl)pyrazolopyrimidines for DPP-4 Inhibition Study

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-carbonitrile and Octahydrocyclopenta[b]pyrrole-2-carbonitrile Derivatives As Dipeptidyl Peptidase IV Inhibitors.

(R)-3-amino-1-((3as,7as)-octahydro-1h-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Derivatives As Potent Inhibitors of Dipeptidyl Peptidase-4: Design, Synthesis, Biological Evaluation, and Molecular Modeling.

Structural Optimization of Pyrazolo[1,5-A]pyrimidine Derivatives As Potent and Highly Selective DPP-4 Inhibitors.

Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay Between the N-terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of Alpha-Aminoacyl-l-cis-4,5-methanoprolinenitrile-based Inhibitors.

Substituted Piperidinyl Glycinyl 2-Cyano-4,5-methano Pyrrolidines As Potent and Stable Dipeptidyl Peptidase IV Inhibitors

Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes

Novel DPP-4 Inhibitors Against Diabetes

Synthesis and Biological Evaluation of Azobicyclo[3.3.0] Octane Derivatives As Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes

Biological Evaluation and In Silico Studies on DPP-IV Inhibition